Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103).

MLA

Bertholet-Thomas, Aurélia, et al. “Bone Mineral Density and Growth Changes in Patients with Distal Renal Tubular Acidosis after Two-Years Treatment with a New Alkalizing Drug (ADV7103).” Nefrologia, vol. 43, no. 4, July 2023, pp. 458–66. EBSCOhost, https://doi.org/10.1016/j.nefroe.2022.02.012.

APA

Bertholet-Thomas, A., Manso-Silván, M. A., Navas-Serrano, V., Guittet, C., Joukoff, S., Bacchetta, J., Boyer, O., Rodriguez Portillo, M., & Granier, L.-A. (2023). Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103). Nefrologia, 43(4), 458–466. https://doi.org/10.1016/j.nefroe.2022.02.012

Chicago

Bertholet-Thomas, Aurélia, Maria A Manso-Silván, Victor Navas-Serrano, Catherine Guittet, Sophie Joukoff, Justine Bacchetta, Olivia Boyer, Mariano Rodriguez Portillo, and Luc-André Granier. 2023. “Bone Mineral Density and Growth Changes in Patients with Distal Renal Tubular Acidosis after Two-Years Treatment with a New Alkalizing Drug (ADV7103).” Nefrologia 43 (4): 458–66. doi:10.1016/j.nefroe.2022.02.012.